MGC 028
Alternative Names: MGC-028Latest Information Update: 08 Aug 2024
At a glance
- Originator MacroGenics
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 06 Aug 2024 MacroGenics plans to initiates a phase I trial for Solid tumours in 2025
- 09 May 2024 Pharmacodynamics and adverse event data from a preclinical trial in Solid tumour released by MacroGenics
- 05 Apr 2024 Pharmacodynamics and adverse event data from a preclinical trial in Solid tumour presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)